On-treatment Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Level and Risk of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B during Nucleot(s)ide Analogue Therapy

On-treatment Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Level and Risk of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B during Nucleot(s)ide Analogue Therapy

We aimed to analyze the serum level of a novel fibrosis marker, Mac-2-binding protein glycosylation isomer (M2BPGi), and its predictive value for hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB) under nucleot(s)ide analogue (NA) therapy. Serum M2BPGi levels were quantified in...

Full description

Bibliographic Details
Main Authors: Ayato Murata, Nozomi Amano, Sho Sato, Hironori Tsuzura, Ko Tomishima, Shunsuke Sato, Kohei Matsumoto, Yuji Shimada, Katsuyori Iijima, Takuya Genda
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:International Journal of Molecular Sciences
Subjects:
chronic hepatitis b
hepatocellular carcinoma
mac-2-binding protein glycosylation isomer
nucleot(s)ide analog
risk factor
Online Access:https://www.mdpi.com/1422-0067/21/6/2051

Internet

https://www.mdpi.com/1422-0067/21/6/2051

Similar Items